Treatment of intracranial aneurysms with the Enterprise stent: a multicenter registry
Clinical article
Search for other papers by J Mocco in
Current site
Google Scholar
PubMed
Search for other papers by Kenneth V. Snyder in
Current site
Google Scholar
PubMed
Search for other papers by Felipe C. Albuquerque in
Current site
Google Scholar
PubMed
Search for other papers by Bernard R. Bendok in
Current site
Google Scholar
PubMed
Search for other papers by Alan S. Boulos in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey S. Carpenter in
Current site
Google Scholar
PubMed
Search for other papers by David J. Fiorella in
Current site
Google Scholar
PubMed
Search for other papers by Brian L. Hoh in
Current site
Google Scholar
PubMed
Search for other papers by Jay U. Howington in
Current site
Google Scholar
PubMed
Search for other papers by Brian T. Jankowitz in
Current site
Google Scholar
PubMed
Search for other papers by Kenneth M. Liebma N in
Current site
Google Scholar
PubMed
Search for other papers by Ansaar T. Rai in
Current site
Google Scholar
PubMed
Search for other papers by Rafael Rodriguez-Mercado in
Current site
Google Scholar
PubMed
Search for other papers by Adnan H. Siddiqui in
Current site
Google Scholar
PubMed
Search for other papers by Erol Veznedaroglu in
Current site
Google Scholar
PubMed
Search for other papers by L. Nelson Hopkins in
Current site
Google Scholar
PubMed
Search for other papers by Elad I. Levy in
Current site
Google Scholar
PubMed
Object
The development of self-expanding stents dedicated to intracranial use has significantly widened the applicability of endovascular therapy to many intracranial aneurysms that would otherwise have been untreatable by endovascular techniques. Recent Food and Drug Administration approval of the Enterprise Vascular Reconstruction Device and Delivery System (Cordis) has added a new option for self-expanding stent-assisted intracranial aneurysm coiling.
Methods
The authors established a collaborative registry across multiple institutions to rapidly provide largevolume results regarding initial experience in using the Enterprise in real-world practice. Ten institutions (University at Buffalo, Thomas Jefferson University, University of Florida, Cleveland Clinic, Northwestern University, West Virginia University, University of Puerto Rico, Albany Medical Center Hospital, the Neurological Institute of Savannah, and the Barrow Neurological Institute) have provided consecutive data regarding their initial experience with the Enterprise.
Results
In total, 141 patients (119 women) with 142 aneurysms underwent 143 attempted stent deployments. The use of Enterprise assistance with aneurysm coiling was associated with a 76% rate of ≥ 90% occlusion. An inability to navigate or deploy the stent was experienced in 3% of cases, as well as a 2% occurrence of inaccurate deployment. Procedural data demonstrated a 6% temporary morbidity, 2.8% permanent morbidity, and 2% mortality (0.8% unruptured, 12% ruptured).
Conclusions
The authors report initial results of the largest series to date in using the Enterprise for intracranial aneurysm treatment. The Enterprise is associated with a high rate of successful navigation and low occurrence of inaccurate stent deployment. The overall morbidity and mortality rates were low; however, caution should be exercised when considering Enterprise deployment in patients with subarachnoid hemorrhage as the authors' experience demonstrated a high rate of associated hemorrhagic complications leading to death.
Abbreviations used in this paper:
FDA = Food and Drug Administration; HDE = Humanitarian Device Exemption; ICA = internal carotid artery; ICH = intracerebral hemorrhage; SAH = subarachnoid hemorrhage.
© Copyright 1944-2023 American Association of Neurological Surgeons